section name header

Indications ⬇

PO:

REMS


Unlabeled Use:
  • PO: Prevention (as monotherapy) and treatment of Pneumocystis jirovecii pneumonia (with trimethoprim or other agents).

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: STEVENS-JOHNSON SYNDROME, exfoliative dermatitis, hypersensitivity reactions (including erythema nodosum leprosum), photosensitivity, systemic lupus erythematosus

EENT: blurred vision, pharyngitis (topical), tinnitus

GI: vomiting, abdominal pain, HEPATOTOXICITY, nausea, PANCREATITIS

Hemat: hemolytic anemia, AGRANULOCYTOSIS, METHEMOGLOBINEMIA, reticulocytosis

Neuro: headache, insomnia, mood changes, peripheral neuropathy, tonic-clonic movements (topical), vertigo

Interactions ⬆ ⬇

Drug-drug:

Drug-Natural Products:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Leprosy

Dermatitis Herpetiformis

Acne Vulgaris

Pneumocystis jiroveciiPneumonia

US Brand Names ⬆ ⬇

Aczone

Action ⬆ ⬇

  • Interferes with folate synthesis in susceptible organisms.
Therapeutic effects:
  • Bacteriostatic action.

Spectrum:

Classifications ⬆ ⬇

Therapeutic Classification: leprostatic agent, anti-infectives

Pharmacokinetics ⬆ ⬇

Absorption: Slowly absorbed (70–80%) following oral administration; acidic environment promotes absorption.

Distribution: Widely distributed; crosses the placenta and enters breast milk in significant concentrations.

Protein Binding: Dapsone: 70–90%; MADDS: 99%.

Metabolism/Excretion: Mostly metabolized by the liver to monoacetyl dapsone (MADDS), its major metabolite, which is then metabolized back to dapsone.

Half-Life: 10–50 hr.

Time/Action Profile ⬆ ⬇

(blood levels)

ROUTEONSETPEAKDURATION
POunknownunknownunknown
Topicalunknownunknownunknown

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

DAP-sohn

Code ⬆

NDC Code